BRPI0910575A2 - métodos para tratar degeneração macular relacionada com a idade, para limitar desenvolvimento de degeneração macular relacionada com a idade, e para identificar compostos para tratar degeneração macular relacionada com a idade, e, composição - Google Patents
métodos para tratar degeneração macular relacionada com a idade, para limitar desenvolvimento de degeneração macular relacionada com a idade, e para identificar compostos para tratar degeneração macular relacionada com a idade, e, composiçãoInfo
- Publication number
- BRPI0910575A2 BRPI0910575A2 BRPI0910575A BRPI0910575A BRPI0910575A2 BR PI0910575 A2 BRPI0910575 A2 BR PI0910575A2 BR PI0910575 A BRPI0910575 A BR PI0910575A BR PI0910575 A BRPI0910575 A BR PI0910575A BR PI0910575 A2 BRPI0910575 A2 BR PI0910575A2
- Authority
- BR
- Brazil
- Prior art keywords
- macular degeneration
- related macular
- age
- treating age
- treating
- Prior art date
Links
- 206010064930 age-related macular degeneration Diseases 0.000 title 3
- 208000002780 macular degeneration Diseases 0.000 title 3
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4704—Inhibitors; Supressors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12462408P | 2008-04-18 | 2008-04-18 | |
PCT/US2009/041021 WO2009129497A2 (en) | 2008-04-18 | 2009-04-17 | Methods and compositions for treating and identifying compounds to treat age-related macular degeneration |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0910575A2 true BRPI0910575A2 (pt) | 2017-06-06 |
Family
ID=41110686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0910575A BRPI0910575A2 (pt) | 2008-04-18 | 2009-04-17 | métodos para tratar degeneração macular relacionada com a idade, para limitar desenvolvimento de degeneração macular relacionada com a idade, e para identificar compostos para tratar degeneração macular relacionada com a idade, e, composição |
Country Status (7)
Country | Link |
---|---|
US (2) | US9173862B2 (pt) |
EP (1) | EP2273988B1 (pt) |
JP (1) | JP2011520788A (pt) |
AU (1) | AU2009236078B2 (pt) |
BR (1) | BRPI0910575A2 (pt) |
CA (1) | CA2721360A1 (pt) |
WO (1) | WO2009129497A2 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120237473A1 (en) * | 2011-03-14 | 2012-09-20 | University Of Medicine And Dentistry Of New Jersey | Compositions And Methods For Cell Based Retinal Therapies |
KR102054904B1 (ko) * | 2011-11-14 | 2019-12-11 | 아스텔라스 인스티튜트 포 리제너러티브 메디슨 | 인간 rpe 세포의 약제학적 제제 및 그의 용도 |
FR3000105B1 (fr) * | 2012-12-24 | 2015-05-15 | Lvmh Rech | Aptameres inhibiteurs de l'activite enzymatique de la tyrosinase |
WO2015029948A1 (ja) * | 2013-08-26 | 2015-03-05 | リンク・ジェノミクス株式会社 | 網膜色素上皮の障害を原因とする網膜疾患の予防または治療剤 |
DK3277660T3 (da) | 2015-03-30 | 2020-01-27 | Berlirem Gmbh | Vandopløselige L-DOPA-estere |
US10314473B2 (en) * | 2015-09-09 | 2019-06-11 | New York University | System and method for in vivo detection of fluorescence from an eye |
JP6898429B2 (ja) * | 2016-08-24 | 2021-07-07 | ナショナル・インスティチュート・オブ・バイオロジカル・サイエンシズ,ベイジン | 黄斑変性症を治療するためのエンタカポン関連化合物 |
CN113286581A (zh) | 2019-01-09 | 2021-08-20 | 扶桑药品工业株式会社 | 用于治疗视网膜疾病的眼内或者口服给药用药物组合物 |
US11969401B2 (en) * | 2019-01-31 | 2024-04-30 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating or limiting development of age-related macular degeneration |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3891696A (en) | 1973-11-02 | 1975-06-24 | Interx Research Corp | Novel, transient pro-drug forms of l-dopa |
US4035507A (en) | 1975-04-17 | 1977-07-12 | Interx Research Corporation | Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease |
US4771073A (en) | 1985-12-30 | 1988-09-13 | Merck & Co., Inc. | Rectally absorbable form of L-dopa |
US4873263A (en) | 1985-12-30 | 1989-10-10 | Merck & Co., Inc. | Rectally absorbable form of L-dopa |
US4663349A (en) | 1985-12-30 | 1987-05-05 | Merck & Co., Inc. | Rectally absorbable form of L-dopa |
JP2586720Y2 (ja) | 1992-09-09 | 1998-12-09 | 有限会社 奈良 | タフティング機のルーパー |
US6653134B2 (en) | 1995-03-28 | 2003-11-25 | Cp Hahnemann University | Isolated stromal cells for use in the treatment of diseases of the central nervous system |
AU7669496A (en) | 1995-11-03 | 1997-05-22 | University Of Kentucky | Method for the intranasal administration of l-dopa prodrugs |
US5686423A (en) * | 1996-02-16 | 1997-11-11 | Department Of Health, The Executive Yuan, Republic Of China | Di-and tri-peptide mimetic compounds for Parkinson's disease |
PE20000728A1 (es) * | 1998-06-26 | 2000-08-21 | Cocensys Inc | Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda |
US20020102581A1 (en) * | 1999-02-19 | 2002-08-01 | Hageman Gregory S. | Diagnostics and therapeutics for ocular disorders |
US20020151526A1 (en) | 2000-10-06 | 2002-10-17 | Gallop Mark A. | Bile-acid prodrugs of L-dopa and their use in the sustained treatment of parkinsonism |
US6660297B2 (en) | 2001-03-23 | 2003-12-09 | Bausch & Lomb Incorporated | Nutritional supplement to treat macular degeneration |
DE10206723A1 (de) * | 2002-02-18 | 2003-09-04 | Ulrich Schraermeyer | Therapie von Erkrankungen des Auges und des Zentralen Nervensystems |
EP1596808A4 (en) | 2003-02-07 | 2007-04-04 | Yissum Res Dev Co | L-DOPA AMID DERIVATIVES AND THEIR USE |
US20040220270A1 (en) * | 2003-03-07 | 2004-11-04 | The Jackson Laboratory | Methods and composition of treating glaucoma by modulating tyrosinase/L-DOPA pathway |
-
2009
- 2009-04-17 BR BRPI0910575A patent/BRPI0910575A2/pt not_active Application Discontinuation
- 2009-04-17 CA CA2721360A patent/CA2721360A1/en not_active Abandoned
- 2009-04-17 US US12/937,669 patent/US9173862B2/en active Active
- 2009-04-17 EP EP09733334.8A patent/EP2273988B1/en active Active
- 2009-04-17 JP JP2011505240A patent/JP2011520788A/ja active Pending
- 2009-04-17 WO PCT/US2009/041021 patent/WO2009129497A2/en active Application Filing
- 2009-04-17 AU AU2009236078A patent/AU2009236078B2/en active Active
-
2015
- 2015-09-18 US US14/858,602 patent/US9861600B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2009129497A3 (en) | 2009-12-03 |
US9173862B2 (en) | 2015-11-03 |
AU2009236078A1 (en) | 2009-10-22 |
CA2721360A1 (en) | 2009-10-22 |
WO2009129497A2 (en) | 2009-10-22 |
EP2273988A2 (en) | 2011-01-19 |
JP2011520788A (ja) | 2011-07-21 |
AU2009236078B2 (en) | 2014-03-06 |
US9861600B2 (en) | 2018-01-09 |
EP2273988B1 (en) | 2015-09-09 |
US20160015665A1 (en) | 2016-01-21 |
US20110044908A1 (en) | 2011-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0910575A2 (pt) | métodos para tratar degeneração macular relacionada com a idade, para limitar desenvolvimento de degeneração macular relacionada com a idade, e para identificar compostos para tratar degeneração macular relacionada com a idade, e, composição | |
BRPI0916684A2 (pt) | Compostos de piperazina, composição, e, processo para combater vegetação indesejada | |
BRPI0920356A2 (pt) | Processo para a preparação de compostos úteis como inibidores de sglt | |
BRPI0919882A2 (pt) | métodos para avaliar padrões de rna | |
BR112014010460A2 (pt) | composto, composição farmacêutica, processo para produzir uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica | |
BRPI1006141A2 (pt) | composições de anticorpo modificado, métodos para preparar e usar as mesmas | |
BR112013009935A2 (pt) | compostos, composição, método e semente tratada | |
BR112013019732A2 (pt) | composições e métodos para tratamento de doenças cardiovasculares | |
BR112013007678A2 (pt) | método para tratamento de doenças alérgicas | |
BRPI0914118A2 (pt) | processo para preparação de látex artificial | |
BRPI0816258A2 (pt) | processo para a preparação de compostos úteis como inibidores de sglt | |
BRPI0909627A2 (pt) | métodos, composições e kits para tratar dores e pruridos | |
BRPI0914614A2 (pt) | 2-arilaminoquinazolinas para tratar doenças proliferativas | |
BRPI0922619A2 (pt) | compostos de plasmalogen, composições farmacêuticas contendo os mesmos e métodos para tratar doenças do envelhecimento | |
BRPI0907525A2 (pt) | Processo para iodização de compostos aromáticos | |
BRPI0911077A2 (pt) | método para tratamento de biomassa | |
BR112012004080A2 (pt) | composições farmacêuticas para tratar ibd | |
BRPI0906836A2 (pt) | Composição aglutinante aquosa para pavimentação, e, método para tratar uma superficie de uma pavimentação | |
ZA201008201B (en) | Novel compositions and methods for treating hyperproliferative diseases | |
BR112012001030A2 (pt) | método para tratar a degeneração macular, e, uso de um composto. | |
BRPI0922836A2 (pt) | processo para a preparação de um sal de succinato monovalente | |
BR112013029318A2 (pt) | composição de bixa orellana para o tratamento da degeneração macular | |
BRPI0921420A2 (pt) | processo para preparar compostos | |
BRPI0909393A2 (pt) | processo para a preparação de polibutadieno | |
BR112012006437A2 (pt) | composições e métodos para tratamento do diabetes e outros distúrbios |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |